TEST EARLY TO IDENTIFY MULTIPLE GENOMIC ALTERATIONS, INCLUDING NTRK* GENE FUSIONS, EGFR,* BRAF,* AND OTHERS

Select patients for treatment with VITRAKVI® based on the presence of an NTRK gene fusion in tumor specimens. An FDA-approved test for NTRK gene fusion is not currently available.1

  • NTRK gene fusions can be identified by sensitive and specific molecular testing2-4

    NGS icon.

    NGS* testing allows for efficient multiplex testing, with the ability to find NTRK gene fusions, as well as other genomic targets, such as EGFR, ALK,* BRAF, HER2,* and KRAS2,5-8*

  • IHC* may be used as a screening diagnostic2

    IHC icon.

    Following a positive TRK* IHC test, confirmation of NTRK gene fusion is needed prior to initiation of VITRAKVI treatment9,a

  • Other tests

    DNA FISH icon.

    DNA FISH* can be used to detect NTRK gene fusions; however, in order to detect fusions at multiple locations, such as the 3 NTRK genes, multiple FISH tests would need to be run6

    • There is utility in using FISH in diseases such as IFS,* where the predominant driver for IFS is ETV6-NTRK310,11
  • RT-PCR icon.

    RT-PCR* is designed to identify only known translocation partners and breakpoints and cannot identify novel breakpoints or novel fusion partners.12

Review prior NGS results to identify the presence of an NTRK gene fusion that may be treatable with VITRAKVI.

Contact your local pathologist or laboratory to test for NTRK gene fusions and TRK fusion proteins

*ALK, anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene; EGFR, epidemal growth factor receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IFS, infantile fibrosarcoma; IHC, immunohistochemistry; KRAS, Kirsten rat sarcoma; NGS, next-generation sequencing; NTRK, neurotrophic receptor tyrosine kinase; RT-PCR, reverse transcription polymerase chain reaction; TRK, tropomyosin receptor kinase. aPan-TRK antibodies are able to detect the TRK proteins A, B, and C across both wild-type and chimeric fusion proteins. Therefore, protein expression may not be related to a gene fusion.2,9

TEST EARLY FOR NTRK* GENE FUSION AND OTHER ACTIONABLE ALTERATIONS

Select patients for treatment with VITRAKVI® based on the presence of an NTRK gene fusion in tumor specimens. An FDA-approved test for NTRK gene fusion is not currently available.1

  • NTRK gene fusions can be identified by sensitive and specific molecular testing2-4

    NGS icon.

    NGS* testing allows for multiplex testing, with the ability to find NTRK gene fusions as well as other genomic targets, such as BRAF,* EGFR,* HER2,* and KRAS.2,5-8*

    • RNA testing may be preferable to DNA testing because it identifies actively transcribed chimeric fusions25
    • Ensure that gene fusion testing of NTRK1, NTRK2, and NTRK3 are included in the NGS panel you order
  • IHC* may be used as a screening diagnostic2

    IHC icon.

    Pan-TRK* antibodies detect TRKA, TRKB, and TRKC proteins, which are known to be conserved across wild-type and chimeric fusion proteins. Therefore, protein expression may not be related to a gene fusion.2 Both in vitro diagnostics (IVS) and research-use only (RUO) antibodies are commercially available.26-28

    • Following a positive TRK IHC test, confirmation of NTRK gene fusion is needed prior to initiation of VITRAKVI treatment9
  • Other tests

    DNA FISH icon.

    DNA FISH* can be used to detect NTRK gene fusions; however, in order to detect fusions at multiple locations, such as the 3 NTRK genes, multiple FISH tests would need to be run.6

    • There is utility in using FISH in diseases such as IFS,* where the predominant driver for IFS is ETV6-NTRK10,11
  • RT-PCR icon.

    RT-PCR* is designed to identify only known translocation partners and breakpoints and cannot identify novel breakpoints or novel fusion partners.12

*BRAF, B-Raf proto-oncogene; EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IFS, infantile fibrosarcoma; IHC, immunohistochemistry; KRAS, Kirsten rat sarcoma virus; NGS, next-generation sequencing; NTRK, neurotrophic receptor tyrosine kinase; RT-PCR, reverse transcription polymerase chain reaction; TRK, tropomyosin receptor kinase.
See the Interactive PI See the Interactive PI

Indication

VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:

  • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
  • are metastatic or where surgical resection is likely to result in severe morbidity, and
  • have no satisfactory alternative treatments or that have progressed following treatment.

This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Important Safety Information

Neurotoxicity: Among the 176 patients who received VITRAKVI, neurologic adverse reactions of any grade occurred in 53% of patients, including Grade 3 and Grade 4 neurologic adverse reactions in 6% and 0.6% of patients, respectively. The majority (65%) of neurologic adverse reactions occurred within the first three months of treatment (range 1 day to 2.2 years). Grade 3 neurologic adverse reactions included delirium (2%), dysarthria (1%), dizziness (1%), gait disturbance (1%), and paresthesia (1%). Grade 4 encephalopathy (0.6%) occurred in a single patient. Neurologic adverse reactions leading to dose modification included dizziness (3%), gait disturbance (1%), delirium (1%), memory impairment (1%), and tremor (1%).

Advise patients and caretakers of these risks with VITRAKVI. Advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dose when resumed.

Hepatotoxicity: Among the 176 patients who received VITRAKVI, increased transaminases of any grade occurred in 45%, including Grade 3 increased AST or ALT in 6% of patients. One patient (0.6%) experienced Grade 4 increased ALT. The median time to onset of increased AST was 2 months (range: 1 month to 2.6 years). The median time to onset of increased ALT was 2 months (range: 1 month to 1.1 years). Increased AST and ALT leading to dose modifications occurred in 4% and 6% of patients, respectively. Increased AST or ALT led to permanent discontinuation in 2% of patients.

Monitor liver tests, including ALT and AST, every 2 weeks during the first month of treatment, then monthly thereafter, and as clinically indicated. Withhold or permanently discontinue VITRAKVI based on the severity. If withheld, modify the VITRAKVI dosage when resumed.

Embryo-Fetal Toxicity: VITRAKVI can cause fetal harm when administered to a pregnant woman. Larotrectinib resulted in malformations in rats and rabbits at maternal exposures that were approximately 11- and 0.7-times, respectively, those observed at the clinical dose of 100 mg twice daily.

Advise women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment and for 1 week after the final dose of VITRAKVI.

Most Common Adverse Reactions (≥20%): The most common adverse reactions (≥20%) were: increased ALT (45%), increased AST (45%), anemia (42%), fatigue (37%), nausea (29%), dizziness (28%), cough (26%), vomiting (26%), constipation (23%), and diarrhea (22%).

Drug Interactions: Avoid coadministration of VITRAKVI with strong CYP3A4 inhibitors (including grapefruit or grapefruit juice), strong CYP3A4 inducers (including St. John’s wort), or sensitive CYP3A4 substrates. If coadministration of strong CYP3A4 inhibitors or inducers cannot be avoided, modify the VITRAKVI dose as recommended. If coadministration of sensitive CYP3A4 substrates cannot be avoided, monitor patients for increased adverse reactions of these drugs.

Lactation: Advise women not to breastfeed during treatment with VITRAKVI and for 1 week after the final dose.

For important risk and use information about VITRAKVI, please see the full Prescribing Information.

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
For Bayer products you can report these directly to Bayer by clicking here.

References:

  • 1. VITRAKVI [package insert]. Stamford, CT: Loxo Oncology, Inc.; November 2018.
  • 2. Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551.
  • 3. Su D, Zhang D, Chen K, et al. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. J Exp Clin Cancer Res. 2017;36(1):1-12.
  • 4. Lih C-J, Harrington RD, Sims DJ, et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: Molecular Analysis for Therapy Choice clinical trial. J Mol Diagn. 2017;19(2):313-327.
  • 5. Park HS, Park S-J, Kim JY, et al. Next-generation sequencing of BRCA1/2 in breast cancer patients: potential effects on clinical decision-making using rapid, high-accuracy genetic results. Ann Surg Treat Res. 2017;92(5):331-339.
  • 6. Rogers T-M, Arnau GM, Ryland GL, et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 2017;7:42259. doi:10.1038/srep42259.
  • 7. Fox AJ, Hiemenz MC, Lieberman DB, et al. Next generation sequencing for the detection of actionable mutations in solid and liquid tumors. J Vis
    Exp.
    2016;115:e52758. doi:10.3791/52758.
  • 8. Boland GM, Piha-Paul SA, Subbiah V, et al. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015;6(24):20099-20110.
  • 9. Murphy DA, Ely HA, Shoemaker R, et al. Detecting gene rearrangements in patient populations through a 2-step diagnostic test comprised of rapid IHC enrichment followed by sensitive next-generation sequencing. Appl Immunohistochem Mol Morphol. 2017;25(7):513-523.
  • 10. Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PHB. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol. 2000;24(7):937-946.
  • 11. Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PHB. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184-187.
  • 12. Abel H, Pfeifer J, Duncavage E. Translocation detection using next-generation sequencing. In: Kulkarni S, Pfeifer J, eds. Clinical Genomics. Amsterdam, Netherlands: Elsevier/Academic Press; 2015:151-164.
  • 13. Vaishnavi A, Le AT, Doeble RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34.
  • 14. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7:129. doi:10.1186/s13073-015-0252-1.
  • 15. Abel HJ, Al-Kateb H, Cottrell CE, et al. Detection of gene rearrangements in targeted clinical next-generation sequencing. J Mol Diagn. 2014;16(4):405-417.
  • 16. Abel HJ, Duncavage EJ. Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches. Cancer Genet. 2013;206(12):432-440.
  • 17. Caris Life Sciences. Tumor profiling services. https://www.carismolecularintelligence.com/wp-content/uploads/2017/03/TN0276-v5_Profile-Menu-Brochure.pdf. Accessed March 13, 2019.
  • 18. Foundation Medicine. FoundationOne CDx Technical Specifications. https://assets.ctfassets.net/vhribv12lmne/
    4ZHUEfEiI8iOCk2Q6saGcU/
    3be7b2679375f1acc6e508
    e323234004/F1CDx_Technical_Specifications.pdf. Accessed March 13, 2019.
  • 19. Integrated Oncology. OmniSeq Comprehensive® Assay. https://www.integratedoncology.com/sites/io/files/inline-files/OmniSeq-Comprehensive.pdf. Accessed March 13, 2019.
  • 20. Navican. TST-170 gene list and variant classification. https://navican.com/assets/pdfs/NAVICAN%20Technical
    %20Details%20and%20Gene%
    20List.pdf. Accessed March 13, 2019.
  • 21. NeoGenomics. NTRK NGS Fusion Profile. https://neogenomics.com/test-menu/ntrk-ngs-fusion-profile. Accessed March 12, 2019.
  • 22. Paradigm Diagnostics. Requisition form. http://www.paradigmdx.com/pcdx/order-pcdx. Accessed May 3, 2018.
  • 23. PathGroup. Solid tumor fusion gene list. http://www.
    pathgroup.com/wp-content/uploads/2013/08/
    PathGroup_Solid-Tumor-Fusion-Gene-List_11.2017-FINAL.pdf. Accessed May 3, 2018.
  • 24. Tempus. xT gene panel. https://s3.amazonaws.com/
    website-tempus-com/files/TempusxTPanelGeneList.pdf. Accessed May 4, 2018.
  • 25. Ozsolak F, Milos PM. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011;12(2):87-98.
  • 26. Roche Tissue Diagnostics. VENTANA pan-TRK (EPR17341) assay. http://reagent-catalog.roche.com/product/1909?type=2442. Accessed November 29, 2018.
  • 27. Abcam. Anti-TrkA + TrkB + TrkC antibody [EPR17341] ab181560. http://www.abcam.com/trka--trkb--trkc-antibody-epr18413-ab189903.html. Accessed May 4, 2018.
  • 28. Cell Signal Technology. Trk (pan) (A7H6R) rabbit mAb #92991. https://www.cellsignal.com/products/primary-antibodies/trk-pan-a7h6r-rabbitmab/92991?_=1525467899111&Ntt=trk&tahead=true. Accessed May 4, 2018.
  • 29. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739.
  • 30. Illumina, Inc. TruSight Oncology 500 Datasheet. https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/trusight
    -oncology-500-datasheet-1170-2018-010.pdf. Accessed March 8, 2019.
  • 31. Illumina, Inc. TruSight® Tumor 170 Datasheet. https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets/trusight-tumor-170-data-sheet-1170-2016-017.pdf. Accessed July 3, 2018.
  • 32. Illumina, Inc. TruSight RNA Fusion Panel Target Genes. https://www.illumina.com/content/dam/illumina-marketing/documents/products/datasheets
    /trusight-tumor-170-data-sheet-1170-2016-017.pdf. Accessed March 8, 2019.
  • 33. Illumina, Inc. TruSight RNA Pan-Cancer Panel Datasheet. https://www.illumina.com/content/dam/illumina-marketing/documents/products/
    datasheets/trusight-rna-pancancer-data-sheet-1170-2015-004.pdf. Accessed July 3, 2018.
  • 34. Thermo Fisher Scientific Inc. An approach for establishing Oncomine Focus Assay performance. https://tools.thermofisher.com/content/sfs/
    brochures/
    oncomine-focus-assay-performance-white-paper.pdf. Accessed September 27, 2018.
  • 35. Thermo Fisher Scientific Inc. Oncomine Comprehensive Assay v3. https://assets.thermofisher.com/TFS-Assets/LSG/brochures/oncomine-comprehensive-assay-v3-flyer.pdf. Accessed September 27, 2018.
  • 36. Thermo Fisher Scientific Inc. Oncomine Childhood Cancer Research Assay Flyer. https://assets.
    thermofisher.com/TFS-Assets/CSD/Flyers/oncomine-childhood-cancer-assay-flyer.pdf. Accessed March 8, 2019.
  • 37. ArcherDX. Archer FusionPlex® Solid Tumor Kit. http://archerdx.com/fusionplex-assays/solid-tumor. Accessed July 3, 2018.
  • 38. ArcherDX, Inc. FusionPlex® Solid Tumor Product Insert. https://cdn2.hubspot.net/hubfs/4445440/Product%
    20inserts/LA179.B%20Product%20Insert,%20FusionPlex
    %20Solid%20Tumor.pdf. Accessed September 27, 2018.
  • 39. ArcherDX, Inc. FusionPlex® Oncology Research Kit. http://archerdx.com/fusionplex-assays/oncology-research. Accessed September 27, 2018.
  • 40. ArcherDX, Inc. FusionPlex® CTL Kit. http://archerdx.com/
    fusionplex-assays/ctl-rna. Accessed September 27, 2018.
  • 41. ArcherDX, Inc. FusionPlex® Lung Product Insert. http://cdn2.hubspot.net/hubfs/4445440/Product%
    20inserts/LA671.B%20Product%20Insert,%20 FusionPlex®%20Lung,%20SK0133.pdf. Accessed March 8, 2019.